Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $31.95 USD
Change Today +0.19 / 0.60%
Volume 597.3K
SRPT On Other Exchanges
As of 3:13 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

sarepta therapeutics inc (SRPT) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/21/15 - $34.66
52 Week Low
01/14/15 - $11.33
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

sarepta therapeutics inc (SRPT) Details

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. Its lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development stage for the treatment of individuals with Duchenne muscular dystrophy (DMD), a rare genetic muscle-wasting disease caused by the absence of dystrophin. The company also focuses on developing therapeutics for the treatment of drug-resistant bacteria, Becker muscular dystrophy, progeria, adult onset pompe, lupus and graft-versus-host diseases; and other rare, genetic, anti-infective, neuromuscular, and central nervous system diseases. The company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

204 Employees
Last Reported Date: 02/26/15
Founded in 1980

sarepta therapeutics inc (SRPT) Top Compensated Officers

Interim Chief Executive Officer, Chief Medica...
Total Annual Compensation: $399.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $443.7K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $393.4K
Senior Vice President of Technical Operations
Total Annual Compensation: $335.9K
Compensation as of Fiscal Year 2014.

sarepta therapeutics inc (SRPT) Key Developments

Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data of Marburg Drug Candidate, AVI-7288, Supporting Safety of the PMOplus® platform

Sarepta Therapeutics, Inc. announced the publication of results from a multiple ascending dose study to determine the safety of AVI-7288, a PMOplus® antisense oligonucleotide, in healthy adult volunteers, in the July 23, 2015 issue of The New England Journal of Medicine. The results of the study, conducted in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), demonstrated no clinical or toxicologic safety concerns with AVI-7288, an investigational treatment for Marburg Virus (MARV) infection. These results add to the continued documentation of safety data for Sarepta's PMO-based technology. AVI-7288 utilizes Sarepta's advanced and proprietary PMOplus® technology. AVI-7288 is designed to bind to viral messenger RNA encoding Marburg Virus nucleoprotein to inhibit nucleoprotein synthesis and prevent viral replication and assembly. This mechanism of AVI-7288 is fundamentally distinct from other RNA-based anti-infective therapies that utilize a gene editing or degradation pathway. Additionally, this approach highlights the flexibility and precision of the PMO-based platform. The Phase I clinical study was a randomized, double-blind, placebo-controlled trial designed to characterize the safety, tolerability and pharmacokinetics of AVI-7288 after daily repeat dosing. Over 14 days, 40 healthy human volunteers (8 per dose group) were dosed with up to 16 mg/kg/day, representing the high continuous dosing of any PMOplus® or any other antisense oligonucleotide. This dosing also exceeded the predicted human efficacious dose for AVI-7288 estimated by three different models based upon nonhuman primate studies demonstrating up to 100% animal survival, including in a delayed time to treat setting.

Sarepta Therapeutics Appoints Henri Termeer as Advisor to the Company

Sarepta Therapeutics, Inc. announced Henri Termeer, industry leader and former CEO of Genzyme, will be a key advisor to the Company. Henri Termeer is the former chairman, president and chief executive officer of Genzyme Corporation, where he served for nearly three decades until retiring in 2011 following the acquisition of Genzyme by Sanofi in a transaction valued at more than $20 billion.

Sarepta Therapeutics, Inc. Secures $40 Million in Debt Financing

Sarepta Therapeutics, Inc. announced that it entered into a credit and security agreement with Midcap Financial that establishes a senior secured term loan facility that allows Sarepta to borrow up to $40,000,000 at an annual rate of 7.75%, with a maturity of June 2018, subject to certain conditions and other applicable fees. Sarepta has drawn down $20,000,000 under the facility and has the right to repay all borrowed funds and terminate the facility at any time.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SRPT:US $31.99 USD +0.23

SRPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Benitec Biopharma Ltd A$0.92 AUD +0.03
Galena Biopharma Inc $1.65 USD -0.0138
Regulus Therapeutics Inc $8.20 USD -0.065
Silence Therapeutics PLC 278.00 GBp -2.37
View Industry Companies

Industry Analysis


Industry Average

Valuation SRPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 355.9x
Price/Book 6.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 310.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAREPTA THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at